Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

PBLA-PR-definitive-agreement-2-22-22

.pdf

Download PDF • 209KB

Featured Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Recent Posts

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem

SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics

Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China

The Sage Group Invites You to a Webinar by Axiom Space on November 30, 2021at 11 AM Eastern Time

The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug

Sage Represents medac GmbH in Deal for Commercialisation Agreement for Treosulfan in Canada

The Sage Group Represents VAL401 - A Unique Formulation of Respiridone for Cancer Supportive Care

IPSC-Derived Cardiomyocyte Product to Treat Chronic Heart Failure Patients - Partnering Opportunity

Archive

Search By Tags

Follow Us